Literature DB >> 4039738

Primary cardiac tumors: experience with 30 consecutive patients since the introduction of two-dimensional echocardiography.

F E Fyke, J B Seqard, W D Edwards, F A Miller, G S Reeder, T T Schattenberg, C Schub, J A Callahan, A J Tajik.   

Abstract

Experience with 30 consecutive patients who had a total of 32 primary cardiac tumors and who underwent two-dimensional echocardiographic examinations between January 1977 and June 1983 was reviewed. Most of the tumors were atrial myxomas (20 left and 4 right), and 30 were identified on echocardiography. Twenty-five patients, including 21 of 22 with atrial myxoma, underwent surgical resection on the basis of the echocardiographic examination, without preoperative angiocardiography. When the morphologic characteristics of the left atrial myxomas were studied statistically in relation to clinical abnormalities, large tumor size was most closely related to the number and type of associated clinical and laboratory abnormalities. The single exception was embolization, which correlated with echocardiographic tumor consistency. Since the introduction of two-dimensional echocardiography, the yearly incidence of cardiac tumor diagnosis at this clinic has increased several fold and the incidence of unexpected intraoperative diagnosis has been very low (one case). Echocardiography is the method of choice for clinical diagnosis. It has replaced angiocardiography for routine preoperative assessment, permits early diagnosis of cardiac neoplasms and provides insight into the pathophysiology of primary cardiac tumors.

Entities:  

Mesh:

Year:  1985        PMID: 4039738     DOI: 10.1016/s0735-1097(85)80364-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  16 in total

1.  The echocardiographic spectrum of atrial myxoma: a ten-year experience.

Authors:  L W Pechacek; F Gonzalez-Camid; R J Hall; E Garcia; C M de Castro; R D Leachman; G Montiel-Amoroso
Journal:  Tex Heart Inst J       Date:  1986-06

2.  Echocardiographically evaluated site of attachment of atrial myxoma may predict recurrence.

Authors:  Balaram Shrestha; Naoko Ishizuka; Kyomi Tanimoto; Hiroshi Kasanuki; Hitoshi Koyanagi
Journal:  J Med Ultrason (2001)       Date:  2003-06       Impact factor: 1.314

3.  Assessment of intracardiac masses by transesophageal echocardiography.

Authors:  J B DeVille; D Corley; B S Jin; C M de Castro; R J Hall; S Wilansky
Journal:  Tex Heart Inst J       Date:  1995

4.  Evaluation by electron beam computed tomography of intracardiac masses suspected by transoesophageal echocardiography.

Authors:  E Mousseaux; A Hernigou; M Azencot; M Sapoval; M Auguste; J C Gaux
Journal:  Heart       Date:  1996-09       Impact factor: 5.994

5.  Star in the heart.

Authors:  K M Krishnamoorthy; J A Tharakan; S R Krishnamanohar
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

6.  "Syndrome myxoma": a subset of patients with cardiac myxoma associated with pigmented skin lesions and peripheral and endocrine neoplasms.

Authors:  H J Vidaillet; J B Seward; F E Fyke; W P Su; A J Tajik
Journal:  Br Heart J       Date:  1987-03

7.  Left atrial myxoma: new perspectives in the diagnosis of murmur free cases.

Authors:  P Nihoyannopoulos; P Venkatesan; J David; D Hackett; H Valantine; C M Oakley
Journal:  Br Heart J       Date:  1986-12

8.  Treatment strategies for pediatric patients with primary cardiac and pericardial tumors: a 30-year review.

Authors:  Thomas Günther; Christian Schreiber; Christian Noebauer; Andreas Eicken; Ruediger Lange
Journal:  Pediatr Cardiol       Date:  2008-07-04       Impact factor: 1.655

9.  Echocardiography of intracardiac filling defects in infants and children.

Authors:  G P Sharratt; A G Lacson; G Cornel; S Virmani
Journal:  Pediatr Cardiol       Date:  1986       Impact factor: 1.655

10.  Papillary fibroelastoma in the left ventricular outflow tract.

Authors:  S Uchida; N Obayashi; H Yamanari; K Matsubara; D Saito; S Haraoka
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.